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ABSTRACT
Background: Differences in outcomes between
bioresorbable vascular scaffold (BVS) systems and
drug-eluting metal stents (DES) have not been fully
evaluated. We aimed to compare clinical and
angiographic outcomes in randomised studies of
patients with coronary artery disease (CAD), with a
secondary analysis performed among registry studies.
Methods: A meta-analysis comparing outcomes
between BVS and DES in patients with CAD. Overall
estimates of treatment effect were calculated with
random-effects model and fixed-effects model.
Results: In 6 randomised trials (3818 patients), BVS
increased the risk of subacute stent thrombosis (ST)
over and above DES (OR 2.14; CI 1.01 to 4.53;
p=0.05), with a trend towards an increase in the risk of
myocardial infarction (MI) (125 events in those
assigned to BVS and 50 to DES; OR 1.36; CI 0.97 to
1.91; p=0.07). The risk of in-device late lumen loss
(LLL) was higher with BVS than DES (mean difference
0.08 mm; CI 0.03 to 0.13; p=0.004). There was no
difference in the risk of death or target vessel
revascularisation (TVR) between the two devices. In 6
registry studies (1845 patients), there was no
difference in the risk of death, MI, TVR or subacute ST
between the two stents. Final BVS dilation pressures
were higher in registry than in randomised studies
(18.7±4.6 vs 15.2±3.3 atm; p<0.001).
Conclusions: Patients treated with BVS had an
increased risk of subacute ST and slightly higher LLL
compared with those with DES, but this might be
related to inadequate implantation techniques, in
particular device underexpansion.
INTRODUCTION
Despite latest-generation drug-eluting metal
stents (DES) demonstrating improved safety
and efﬁcacy compared with ﬁrst-generation
implants,1 there remains the need for better
devices for percutaneous coronary interven-
tion (PCI). Recent clinical studies using the
ﬁrst commercially available bioresorbable vas-
cular scaffold (BVS) systems have reported
promising results. Unlike DES, BVS poten-
tially allow restoration of anatomy and
vascular function. This novel technology
offers the promise of eliminating late stent
failure related to thrombosis and neoathero-
sclerosis that is associated with the presence
of a permanent metallic foreign body.
However, in early registry studies, BVS use
was associated with higher rates of stent
thrombosis (ST) in the ﬁrst 6 months,2–4 pos-
sibly due to suboptimal device expansion
and insufﬁcient intracoronary imaging
guidance.
The currently available data from individ-
ual randomised trials and observational
studies suggest that clinical outcomes are
otherwise similar between patients treated
with DES or BVS,5–16 though most studies
are limited by a small sample size. The aim
of this meta-analysis was to evaluate the efﬁ-
cacy and safety of BVS, compared with DES,
KEY QUESTIONS
What is already known about this subject?
▸ Recent clinical studies using the first commer-
cially available bioresorbable vascular scaffold
systems have reported promising results.
However, the rate of subacute stent thrombosis
was observed to be higher than expected after
implantation of these devices, possibly due to
suboptimal device expansion and insufficient
intracoronary imaging guidance.
What does this study add?
▸ The aim of this study was to evaluate the effi-
cacy and safety of bioresorbable vascular scaf-
fold systems, compared with drug-eluting metal
stents, using the data available from randomised
and observational studies, with a focus on stent
implantation techniques.
How might this impact on clinical practice?
▸ When using bioresorbable vascular scaffold
systems, every effort should be made to select
suitable patients, with careful lesion preparation,
and with intervention guided by adequate intra-
vascular device optimisation.
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using the data available from randomised trials, with a
focus on stent implantation techniques. We also per-
formed an analysis of data from observational studies in
order to determine outcomes in the ‘real-world’ setting.
METHODS
Study objectives and design
The outcomes of interest were death, myocardial infarc-
tion (MI), target vessel revascularisation (TVR), ST and
in-device late lumen loss (LLL) at angiographic
follow-up, deﬁned according to the study protocols. We
also performed a secondary analysis for death, MI, TVR
and ST for registry studies. The study was designed
according to the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-analyses) statement and
the Meta-Analysis of Observational Studies in
Epidemiology (MOOSE) work groups.17 18
Study search strategy
Using MEDLINE, Embase, Scopus and the Cochrane
Library, we performed searches of articles published
until December 2015, without language restrictions.
Eligible studies were identiﬁed using various combina-
tions of the terms: absorb, bioresorbable, drug-eluting
stent, percutaneous, coronary, MI, angina, angioplasty
and intervention in the abstract or title. Reference lists
of the retrieved articles were reviewed to identify eligible
studies. Online oral presentations and expert slide pre-
sentations were also examined. Two reviewers independ-
ently reviewed all titles, or titles and abstracts from the
search results to identify articles according to fulﬁlment
of inclusion criteria. Selected trials were compared, and
disagreement was resolved by team discussion and con-
sensus. Studies were excluded from the meta-analysis if
they included the use of bare-metal stent, reported
duplicate or incomplete interim data, had small sample
size of ≤50 patients or short follow-up of <3 months or
were single-arm studies.
Data extraction
Data extraction was carried out independently and in
duplicate by the study investigators. Results of data
extraction were then compared, and discrepancies
resolved by consensus. If results were incomplete or
unclear, the study authors were contacted. Articles
selected for the ﬁnal review were checked to avoid inclu-
sion of data published in duplicate. Data were collated
from each study regarding baseline characteristics,
including study design, device type, sample character-
istics, ACC/AHA lesion classiﬁcation, glycoprotein IIb/
IIIa inhibitors (GPI) use, use of intracoronary imaging,
predilation and postdilation pressures, duration of dual
antiplatelet therapy and procedural and clinical out-
comes at the end of follow-up. If TVR was not reported,
we used target lesion revascularisation instead. As for ST,
we pooled outcomes for any ST, including deﬁnite, prob-
able and possible ST. All outcomes were deﬁned
according to the original study’s protocol deﬁnition. ST
was deﬁned according to the Academic Research
Consortium criteria19 in all included studies. When a
study reported follow-up at 1 and 2 years, outcomes for
the longer time periods were abstracted.
Statistical analysis
Outcomes are presented as OR with 95% CI. Pooled OR
was calculated for categorical and continuous variables
using a random-effects model by the method of
DerSimonian and Laird.20 Heterogeneity was assessed
using χ2 and I2 tests. We also used the Mantel-Haenszel
ﬁxed-effects model, when no heterogeneity was observed
(ie, I2=0%). All analyses were performed with the
intention-to-treat principle. In sensitivity analysis, we
included only registry studies which directly compared
BVS with DES in coronary artery disease (CAD). We did
meta-regression to examine the relationship between the
log-transformed OR of the effect of BVS on ST risk and
the log-transformed OR of the effect of BVS on mortal-
ity, in identiﬁed randomised trials. We used the unpaired
two-sample mean comparison Student’s t-test to
compare weighted means of different populations, in
particular those related to stent technical parameters
(ie, BVS ﬁnal dilation pressure).
Publication bias was minimised by a comprehensive
and inclusive literature search. In addition, a graphical
display (funnel plot) of the size of the treatment effect
against the precision of the trial (1/SE) was used to
investigate publication bias. All tests were two-sided, and
statistical signiﬁcance was ﬁxed at 0.05 level. Analysis was
carried out using Review Manager Software (RevMan
V.5.3) and Stata V.11.2 (StataCorp, College Station,
Texas, USA).
RESULTS
Six randomised trials involving 3818 patients were identi-
ﬁed, which directly compared the clinical outcomes of
BVS versus DES in CAD (see online supplementary
ﬁgure S1).5–10 Six registry studies11–16 involving 1845
patients that compared clinical outcomes of BVS against
DES were also included. Of these, three performed pro-
pensity score matched-sample analyses.11 13 14 The meth-
odological quality of included studies is described in
online supplementary tables S1 and S2. The primary
outcomes of included studies are listed in online supple-
mentary tables S3 and S4. There was no evidence of
publication bias having a signiﬁcant effect on the results
(see online supplementary ﬁgure S2).
The characteristics of randomised trials are listed in
table 1. Greater than three-quarters of patients were
male with a mean age of 62±4 years, 28.4% patients with
diabetes and ACC/AHA lesion class was B2/C in 66.2%.
All trials included patients with acute coronary syn-
dromes (table 1). The median follow-up was 12 months.
Patients randomised to receive BVS (n=2337) were
treated with the Absorb everolimus-eluting scaffold
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(Abbott Vascular, Santa Clara, California, USA). BVS
postdilation was performed in 64.8% of patients up to a
mean maximum pressure of 15.2±3.3 atm. Intravascular
imaging (OCT/IVUS) was used to guide BVS expansion
in 33.2% of cases. Patients randomised to receive DES
(n=1401) were treated with either an everolimus-eluting
cobalt–chromium stent (Xience Prime, Xience V, or
Xience Xpedition; Abbott Vascular, Santa Clara,
California, USA), an everolimus-eluting platinum–chro-
mium stent (Promus Element; Boston Scientiﬁc, Natick,
Massachusetts, USA) or a biolimus-eluting stainless-steel
stent (Biomatrix Flex; Biosensors, Europe, SA). Four of
the clinical trials’ primary end points were based on
angiographic criteria.5–8 In one trial, a 2-year interim
clinical outcomes report was only available online, and
these results were used.9 All interventions were per-
formed according to standard of care, including opti-
misation of stent deployment or use of intravascular
imaging techniques, according to trial protocols. All
patients were prescribed long-term aspirin, whereas the
use of dual antiplatelet therapy varied between 6 and
12 months. All trials reported the adherence to dual
Table 1 Baseline patient and lesion characteristics of randomised trials
ABSORB II,
2015
ABSORB III,
2015
ABSORB
CHINA, 2015
ABSORB
JAPAN, 2015
EVERBIO II,
2015
ABSORB STEMI
TROFI II ST, 2016
Patients (n) 501 2008 480 400 238 191
BVS (n) 335 1322 241 266 78 95
DES (n) 166 686 239 134 160 96
Male (%) 77 70 72 77 79 82
Mean age (year) 61 63 57 67 65 59
Diabetes (%) 24 31 24 36 23 16
Follow-up (months) 24 12 12 12 9 6
GPI use (%)
BVS NR 10.1 NR NR NR 40
DES NR 12.4 NR NR NR 38.5
DAPT duration
(months)
Up to 24 12 12 12 6 12
Device type BVS, EES BVS, EES BVS, EES BVS, EES BVS, EES,
BES
BVS, EES
Intracoronary imaging used (OCT/IVUS %)
BVS 100 11.2 0.4 100 NR 0
DES 100 10.8 0.4 100 NR 0
ACC/AHA lesion class (%)
A 1.1 NR 9.5 3.8 24.9 NR
B1 52.1 NR 21.7 20.1 44 NR
B2 45.3 69.9* 49 53.8 15 NR
C 1.4 24.5 22 16 NR
Device predilation (%)
BVS 100 100 99.6 100 NR 55.8
DES 99 100 98 100 NR 51
Device postdilation (%)
BVS 61 65.5 63 82.2 34 50.5
DES 59 51.2 54.4 77.4 31 25.5
Expected maximum diameter of postdilation balloon (mm)
BVS 3.29 3.18 3.3 3.34 NR 3.51
DES 3.35 3.12 3.2 3.31 NR 3.29
Final dilation pressure (atm)
BVS 14.2 15.4 16.8 14.7 13.6 15.8
DES 15 15.4 16.9 15.1 14.2 18.6
Clinical presentation (%)
STEMI 0 0 0 0 9.6 100
Non-STEMI 0 0 0 0 21 0
Unstable angina 20.9 26 64.4 12 8.4 0
Stable angina 63.8 58.4 19.5 64.5 48.3 0
Silent ischaemia 12.1 10 4.6 23.5 12.6 0
Values are means or (%).
*B2+C lesions.
BES, biolimus-eluting stent; BVS, bioresorbable vascular scaffold; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; EES, everolimus
eluting stent; GPI, glycoprotein IIb/IIIa inhibitors; IVUS, intravascular ultrasound; NR, not reported; OCT, optical coherence tomography;
STEMI, ST-elevation myocardial infarction.
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antiplatelet therapy to be >80% up to the longest
follow-up period available.
In the randomised trials, there was no difference in
the risk of death (OR 1.29; CI 0.43 to 3.83; I2=23%;
p=0.65) (ﬁgure 1A) or TVR (OR 1.15; CI 0.83 to 1.59;
I2=0%; p=0.40 (p=0.38 by ﬁxed-effect model)) (ﬁgure 1B)
between the two devices. Compared with DES, patients
treated with BVS showed a trend towards an increase in
the risk of MI (125 events in those assigned to BVS and
50 to DES; OR 1.36; CI 0.97 to 1.91; I2=0%; p=0.07)
(p=0.06 by ﬁxed-effect model)) (ﬁgure 1C). Patients
treated with BVS had a higher rate of any ST (deﬁnite,
probable or possible ST; with the majority of events
occurring within 30 days; n=39) compared with those
treated with DES (OR 2.14; CI 1.01 to 4.53; I2=0%;
p=0.05 (p=0.03 by ﬁxed-effect model)) (ﬁgure 2A).
Deﬁnite ST occurred in 33 (0.9%) patients. There was a
trend towards an increase in the risk of deﬁnite ST (27
events in those assigned to BVS and 6 to DES; OR 2.11;
CI 0.92 to 4.88; I2=0%; p=0.08) (p=0.07 by ﬁxed-effect
model)) (ﬁgure 2B). There was no correlation between
the increase in ST risk with BVS and mortality among
the trials reporting at least one ST and death event
(p=0.66; ﬁgure 3).
In trials with angiographic surveillance, the median
angiographic follow-up was 10.5 months (IQR 7.5–12.5).
Coronary lesions treated with BVS had signiﬁcantly
higher in-device LLL at angiographic follow-up than
those treated with DES (mean difference between
groups 0.08 mm; CI 0.03 to 0.13; I2=52%; p=0.004)
(ﬁgure 2C).
The characteristics of registry studies are listed in table 2.
Greater than three-quarters of patients enrolled were male
with a mean age of 62±3 years, 18.2% patients with diabetes
and ACC/AHA lesion class was B2/C in 84.7%. All studies
included patients with acute coronary syndromes (table 2).
The median follow-up was 8 months. Patients receiving
BVS (n=785) were treated with the Absorb
everolimus-eluting scaffold. BVS postdilation was per-
formed in 60.0% of all patients up to a mean maximum
pressure of 18.7±4.6 atm. Intravascular imaging (OCT/
IVUS) was used to guide BVS expansion in 63.7% of cases.
Patients receiving DES (n=1060) were treated with an
everolimus-eluting cobalt–chromium stent (Xience Prime,
Xience Pro, Xience V, or Xience Xpedition; Abbott
Vascular, Santa Clara, California, USA), an
everolimus-eluting platinum–chromium stent (Promus,
Promus Element, Premier; Boston Scientiﬁc, Natick,
Figure 1 Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS)
versus drug-eluting stent (DES) in randomised trials in coronary artery disease. (A) Death, (B) TVR and (C) MI.
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Massachusetts, USA), a biolimus-eluting stainless-steel stent
(N-BES, Nobori; Terumo, Tokyo, Japan) or a
zotarolimus-eluting cobalt–chromium stent (Medtronic
Vascular, Santa Rosa, California, USA). All patients were
prescribed long-term aspirin and dual antiplatelet therapy
was given for 12 months. Only one study reported the
adherence to prescribed dual antiplatelet therapy in the
BVS arm up to 12 months, to be 100%.11
In registry studies, there was no difference in the risk
of death (OR 0.64; CI 0.27 to 1.48; I2=0%; p=0.30
(p=0.22 by ﬁxed-effect model)) (ﬁgure 4A), TVR (OR
0.85; CI 0.49 to 1.48; I2=0%; p=0.57 (p=0.54 by
ﬁxed-effect model)) (ﬁgure 4B), MI (OR 1.37; CI 0.77
to 2.43; I2=0%; p=0.28) (p=0.30 by ﬁxed-effect model))
(ﬁgure 4C), any ST (OR 1.21; CI 0.58 to 2.51; I2=0%;
p=0.61 (p=0.35 by ﬁxed-effect model)) (ﬁgure 5A) or
deﬁnite ST (OR 1.27; CI 0.58 to 2.82; I2=0%; p=0.55)
(p=0.65 by ﬁxed-effect model)) (ﬁgure 5B) between the
two devices.
The results observed in all included registry studies
were also observed within the three studies that had dir-
ectly compared BVS with DES (see online supplemen-
tary ﬁgure S3). Final BVS dilation pressures were higher
in registries than in randomised trials (18.7±4.6 vs 15.2
±3.3 atm; p<0.001), with a mean diameter of postdilation
balloons of 3.4±0.3 vs 3.2±0.4 mm, respectively.
DISCUSSION
The major ﬁndings of this meta-analysis of six rando-
mised trials, involving 3818 patients undergoing PCI, are
that patients treated with BVS have an increased risk of
subacute ST associated with a trend towards an increased
risk of MI, compared with those treated with DES. There
was also a greater in-device LLL with BVS. However, this
was with no difference in TVR or mortality. A difference
Figure 2 Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS)
versus drug-eluting stent (DES) in randomised trials in coronary artery disease. (A) any ST, (B) definite ST and (C) in-device LLL.
Figure 3 Relationship between stent thrombosis (ST) and
mortality, restricted to trials with at least one ST and death
event. Slope of the regression line −0.53, p=0.6556.
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in ST rates was not detected among the 1845 patients
from the 6 registry studies, and rates for death, TVR and
MI were similar in BVS and DES treated patients.
In randomised trials, the rate of subacute ST was
higher with BVS compared with DES, with an overall
rate of 1.39% in 2309 patients receiving BVS and 0.49%
in 1462 patients receiving DES at 12 months. Although
postdilation was more frequently performed in the BVS
group (table 1), the ﬁnal result is considered insufﬁcient
for adequate BVS implantation as currently recom-
mended. In randomised trials, BVS postdilation was per-
formed in 64.8% of cases, with ﬁnal dilation pressures of
Table 2 Baseline patient and lesion characteristics of registry studies
Mattesini et al16
Gori
et al15 Sato et al11
Cortese
et al12 BVS-EXAMINATION13
Costopoulos
et al14
Patients (n) 73 253 192 563 580 184
BVS (n) 35 150 96 122 290 92
DES (n) 38 103 96 441 290 92
Male (%) 79 72 89 78 80 87
Mean age
(years)
62 62 66 59* 57 63
Diabetes (%) 31 17 23 17 13 27
Follow-up
(months)
8 6 12 8* 12 6
GPI use (%)
BVS NR 38.7 NR 34.8 67.5 NR
DES NR 11.7 NR 37.4 51.7 NR
DAPT duration
(months)
NR 12 12 12 12 12
Device type BVS, EES, ZES BVS, EES BVS, BES, EES BVS, EES BVS, EES BVS, EES
Intracoronary imaging used (OCT/IVUS %)
BVS 100 NR 91.7 4.4 NR 99.8
DES 100 NR 64.6 0.4 NR 16.8
ACC/AHA lesion class (%)
A 0 NR NR NR NR NR
B1 0 NR NR NR NR NR
B2 31 NR 84.1† NR NR 80.8†
C 69 NR NR NR
Device predilation (%)
BVS 100 100 100 94.1 81 97.8
DES 100 100 72.1 60 29 75.8
Device postdilation (%)
BVS 100 14 100 94.1 36.3 99.3
DES 100 14 86.4 37.9 15.2 77.4
Expected maximum diameter of postdilation balloon (mm)
BVS 3.5 NR 3.2 3.5 NR 3.2
DES 3.5 NR 3.15 3.5 NR 3.1
Final dilation pressure (atm)
BVS 21.3 15.3 21.1 10* NR 20.9
DES 17.1 12.2 18.4 14 NR 19.0
Clinical
presentation (%)
All-comers
STEMI 0 40.7 100 100 11.4‡
Non-STEMI 0 41.8 0 0
Unstable
angina
4.1 17.3 0 0
Stable angina 95.8 0 0 0 88.6
Silent
ischaemia
0 0 0 0 0
Values are means unless otherwise specified or (%).
*Expressed as median.
†B2+C lesions.
‡Acute coronary syndrome.
BES, biolimus-eluting stent; BVS, bioresorbable vascular scaffold; DAPT, dual antiplatelet therapy; EES, everolimus-eluting stent; GPI,
glycoprotein IIb/IIIa inhibitors; IVUS, intravascular ultrasound; NR, not reported; OCT, optical coherence tomography; STEMI, ST-elevation
myocardial infarction; ZES, zotarolimus-eluting stent.
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Figure 4 Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS)
versus drug-eluting stent (DES) in registry studies in coronary artery disease. (A) Death, (B) TVR and (C) MI.
Figure 5 Any and definite stent thrombosis (ST) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in
registry studies in coronary artery disease. (A) Any ST and (B) definite ST.
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15.2±3.3 atm. The use of intravascular imaging (OCT/
IVUS) guidance for vessel sizing and implant optimisa-
tion is recommended for BVS, but we found that this
was performed in only a third of patients. In a recent
multicentre study involving 1305 patients, the rate of ST
with BVS was as high as 3%, but this was signiﬁcantly
reduced (by ∼70%) when optimal implantation strategy
was employed.21 It is noteworthy that in registries that
used high-pressure (≥20 atm) BVS postdilation, and
routine intravascular imaging guidance, there did not
appear to be an increased risk of ST,11 14 16 and this
probably shaped the ﬁndings of the meta-analysis of
registry studies. Thus, a potential explanation for the
observed increased risk of ST in the randomised trials
may relate to suboptimal implantation techniques,
rather than to the intrinsic properties of BVS.
Furthermore, given the small number of patients
included in this meta-analysis, it is also possible that the
randomised trials were underpowered to detect a differ-
ence with respect to rare complications such as ST.
Nevertheless, since ST is a rare but catastrophic compli-
cation, the available data provide cause for caution.
The Absorb BVS is a thick-strut scaffold, with the
average strut thickness of 157 μm, which is almost
equivalent to that of the ﬁrst-generation Cipher stent
(Cipher Bx Velocity 152.6 mm, Cordis Corporation,
Johnson & Johnson, Warren, New Jersey, USA), and
about double that of the second-generation Xience stent
(Xience V 81.3 mm).22 Indeed, the strut thickness is
considered its main limitation, since it makes for a
bulkier device which may prove challenging to pass
across tortuous vessels or complex calciﬁed lesions.
Additionally, thick-strut, when compared with thin-strut,
stents are associated with higher rates of angiographic
restenosis and are considered to be thrombogenic.23 24
Thus, there may be increased neointimal thickness and
thrombogenicity with BVS indicating perhaps the need
to explore the requirement for long-term adjunct antith-
rombotic pharmacotherapy.
Despite the apparent difference in in-device LLL at
median angiographic follow-up, this was not reﬂected in
any difference in overall revascularisation rates for BVS
versus DES at 1 year. Whether the observed greater loss
in BVS lumen area beyond the ﬁrst year after implant-
ation translates into worse clinical outcomes is unknown.
PCI techniques continue to rapidly evolve with improve-
ments in stent platforms and adjunctive antiplatelet and
antithrombotic therapy. With longer planned follow-up,
the ABSORB II,25 ABSORB IV (NCT02173379) and
AIDA26 trials will provide valuable insight into the long-
term outcomes of BVS, particularly outcomes related to
late and very late ST and lumen area.
In the studies included in this meta-analysis, the
majority of patients were stable and had simple de novo
lesions. Randomised trials included a higher percentage
of patients with diabetes than did registries (28.4% vs
18.2%), but of note, the lesions were less complex
(ACC/AHA lesion class was B2/C in 66.2% of
randomised trials vs 84.7% of registries). Despite the fact
that virtually every study conducted in the era of stenting
has shown higher event rates in patients with diabetes,27
there have been no head-to-head comparisons of out-
comes comparing BVS in patients with and without dia-
betes. Muramatsu et al28 presented promising post hoc
analyses 1 year after BVS implantation showing no differ-
ence in clinical outcomes, particularly in the incidence
of subacute ST, with numerically low ST events in
patients with diabetes.
Our results are in line with two previous meta-analyses
by Cassese et al29 and Lipinski et al30 showing a higher
incidence of ST and MI in the ﬁrst year after BVS
implantation. However, Stone et al31 did not demonstrate
the same pattern in a patient level, pooled meta-analysis
of four randomised trials involving 3389 patients with
CAD. Recently, a network meta-analysis of 147 trials
showed that BVS had an increased risk of ST compared
with contemporary DES.32 Our meta-analysis of data
from randomised and registry studies suggest that this
might indeed be related to inadequate implantation
techniques, in particular to device underexpansion.
Our meta-analysis has several limitations. First, most
studies used strict selection criteria and so, high-risk
patients might not have been assessed, such as those with
tortuous or calciﬁed lesions. Second, all patients receiv-
ing BVS were treated with everolimus-eluting scaffold, in
contrast to patients who received DES where the vast
majority were treated with everolimus-eluting stent, and
small numbers were treated with either biolimus-eluting
stent7 11 or zotarolimus-eluting stent.16 It is however
important to recognise that biolimus-eluting and
zotarolimus-eluting stents had similar safety and efﬁcacy
as the everolimus-eluting stent in prior studies,33 34 and
their inclusion is unlikely to confound the results of the
meta-analysis. Third, three registry studies were propen-
sity score matched-sample analyses, which did not directly
compare the two devices.11 13 14 However, a sensitivity
analysis showed the same results when those studies were
excluded. Fourth, data on adherence to dual antiplatelet
therapy were unavailable in all but one registry.
Furthermore, the studies included had some differences
in design, deﬁnitions and follow-up periods. For rando-
mised trials, the results of this meta-analysis are derived
from study data and not from patient data. Availability of
individual patient data could improve the reliability of
the ﬁndings and permit more ﬂexible analyses.
Additionally, in one of the trials, 2-year results had been
presented but not published.9 Finally, the randomised
trials included were either single-blind or open-label with
a potential for high performance bias.
Whether the higher risk of subacute ST observed with
BVS reﬂects suboptimal implantation technique, thick-
strut scaffold and/or lesion selection remains to be
determined. Data from large observational studies are
still needed, to conﬁrm that BVS can deliver the same
results as DES with the appropriate implantation techni-
ques. Adequately powered randomised trials of BVS
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using careful lesion preparation and device optimisation
are needed, with angiographic follow-up to assess clin-
ical outcomes. Until then, caution must be exercised
and when using BVS, every effort made to select suitable
patients, with careful lesion preparation, with interven-
tion guided by intravascular optimisation to embed the
struts deeply in the vessel wall to avoid malapposition
and to promote rapid endothelialisation.
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